The low-dose version of Tirzepatide has been reduced by over 50% in price

On August 27, 2024, Eli Lilly announced the expansion of its supply of Zepbound, a weight loss version of Tirzepatide, to meet strong clinical demand. The new prices for 2.5mg and 5.0mg doses are $99.75/tube and $137.25/tube, respectively, with corresponding monthly costs of $399 and $549, respectively, representing a price reduction of over 50%.

About Tirzepatide

Tirzepatide is a dual agonist of glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor, which can simultaneously activate GLP-1 receptor and GIP receptor-mediated signaling pathways. GIP and GLP-1 are natural intestinal insulinotropic hormones that regulate blood sugar. Tirzepatide was approved by the US FDA (trade name: Mounjaro) in May 2022 for use in combination with diet control and exercise to improve the blood sugar control of adult type 2 diabetes patients. Last November, tirzepatide received FDA approval again (trade name: Zepbound) for the purpose of reducing weight and maintaining weight stability in obese or overweight adult patients.